Q-omics provides the consensus-scored F7 profile across patient tissues and cancer cell-line models. F7 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, F7 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, F7 protein abundance shows 15,766 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where F7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for F7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes F7 survival associations across molecular data types. F7 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible F7 RNA expression–survival associations across cancer types. High F7 expression shows unfavorable associations in KIRC and UVM, but favorable associations in KICH, LGG, SKCM and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for F7 RNA expression.
This table summarizes F7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for F7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. F7 shows lower tumor expression in KIRC and CHOL and higher tumor expression in COAD, BRCA, THCA and STAD. The COAD box plot shows higher F7 RNA expression in tumor versus normal tissue (log2 FC = +0.967, t-test p < 0.001).
This table shows molecular features associated with F7 in patient tissues and cancer cell lines. In patient samples, F7 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, F7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
